<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02168608</url>
  </required_header>
  <id_info>
    <org_study_id>EHBHKY2013-003-006</org_study_id>
    <nct_id>NCT02168608</nct_id>
  </id_info>
  <brief_title>Remote Ischemia Precondition (RIPC) for Hepatic Protection in Patients Undergoing Hepatectomy</brief_title>
  <official_title>Remote Ischemia Precondition for Hepatic Protection in Patients Undergoing Hepatectomy: A Single-center Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eastern Hepatobiliary Surgery Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eastern Hepatobiliary Surgery Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Remote ischemia precondition could protect the liver from ischemia reperfusion injury in
      patients undergoing hepatectomy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Remote ischemia precondition (RIPC) had been proofed beneficial to ischemia reperfusion
      injury of heart, kidney, liver, brain and spinal cord in experimentation on animals. And the
      clinical studies of RIPC were mainly focused on heart, RIPC's protection effect on hepatic
      ischemia reperfusion injury in patients undergoing hepatectomy still remains unknown, So we
      designed this study to demonstrate the hypotheses.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>survival rate</measure>
    <time_frame>30 days postoperatively</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>alanine aminotransferase (ALT) level in patients' blood</measure>
    <time_frame>1 day postoperatively</time_frame>
    <description>Examine the patients's blood sample for ALT level at 1 day postoperatively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>aspartic transaminase (AST) level in patients' blood</measure>
    <time_frame>1 day postoperatively</time_frame>
    <description>Examine the patients's blood sample for AST level at 1 day postoperatively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>alanine aminotransferase (ALT) level in patients' blood</measure>
    <time_frame>3 days postoperatively</time_frame>
    <description>Examine the patients's blood sample for ALT level at 3 days postoperatively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>aspartic transaminase (AST) level in patients' blood</measure>
    <time_frame>3 days postoperatively</time_frame>
    <description>Examine the patients's blood sample for AST level at 3 days postoperatively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>alanine aminotransferase (ALT) level in patients' blood</measure>
    <time_frame>7 days postoperatively</time_frame>
    <description>Examine the patients's blood sample for ALT level at 7 days postoperatively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>aspartic transaminase (AST) level in patients' blood</measure>
    <time_frame>7 days postoperatively</time_frame>
    <description>Examine the patients's blood sample for AST level at 7 days postoperatively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>complications</measure>
    <time_frame>30 days postoperatively</time_frame>
    <description>Number of participants with adverse events within 30 days postoperatively</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Liver Neoplasms</condition>
  <arm_group>
    <arm_group_label>Remote ischemia precondition</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients in this arm accepted RIPC procedure after induction of anesthesia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>None remote ischemia precondition</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients in this arm didn't accept RIPC procedure after induction of anesthesia</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Remote ischemia precondition</intervention_name>
    <description>Three cycles of 5-min ischemia/5-min reperfusion induced by a blood pressure cuff placed on the right upper arm served as RIPC stimulus.</description>
    <arm_group_label>Remote ischemia precondition</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>None remote ischemia precondition</intervention_name>
    <description>Placed an uninflated cuff on the right upper arm for 30 min.</description>
    <arm_group_label>None remote ischemia precondition</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  No other main organ diseases, American society of Anesthesiologists (ASA)
             classification Ⅰ-Ⅱ grade

          -  Selective hepatectomy, one time hepatic portal occlusion

          -  Child-Pugh A

        Exclusion Criteria:

          -  Peripheral vessels diseases

          -  Not the same surgical procedure as expected

          -  Administered anti-inflammatory drugs as glucocorticoid etc

          -  Diagnosed of diabetes

          -  History of liver surgery

          -  History of hepatic interventional therapy, radiofrequency therapy,radiotherapy and
             chemotherapy

          -  Refuse to join the research

          -  Patients with psychopathy

          -  Acute infection need antibiotic therapy

          -  Hepatic artery or portal vein embolism
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Weifeng Yu, professor</last_name>
    <role>Study Chair</role>
    <affiliation>Eastern Hepatobiliary Surgery Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Weifeng Yu, professor</last_name>
    <phone>86-10-81875231</phone>
    <email>ywf808@sohu.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Eastern Hepatobiliary Surgery Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200438</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Weifeng Yu, professor</last_name>
      <phone>86-10-81875231</phone>
      <email>ywf808@sohu.com</email>
    </contact>
    <investigator>
      <last_name>Weifeng Yu, professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zhi Li, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yuming Sun, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Kin H, Zhao ZQ, Sun HY, Wang NP, Corvera JS, Halkos ME, Kerendi F, Guyton RA, Vinten-Johansen J. Postconditioning attenuates myocardial ischemia-reperfusion injury by inhibiting events in the early minutes of reperfusion. Cardiovasc Res. 2004 Apr 1;62(1):74-85.</citation>
    <PMID>15023554</PMID>
  </reference>
  <reference>
    <citation>Huguet C, Addario-Chieco P, Gavelli A, Arrigo E, Harb J, Clement RR. Technique of hepatic vascular exclusion for extensive liver resection. Am J Surg. 1992 Jun;163(6):602-5.</citation>
    <PMID>1595841</PMID>
  </reference>
  <reference>
    <citation>Delva E, Camus Y, Nordlinger B, Hannoun L, Parc R, Deriaz H, Lienhart A, Huguet C. Vascular occlusions for liver resections. Operative management and tolerance to hepatic ischemia: 142 cases. Ann Surg. 1989 Feb;209(2):211-8.</citation>
    <PMID>2916865</PMID>
  </reference>
  <reference>
    <citation>Clavien PA, Yadav S, Sindram D, Bentley RC. Protective effects of ischemic preconditioning for liver resection performed under inflow occlusion in humans. Ann Surg. 2000 Aug;232(2):155-62.</citation>
    <PMID>10903590</PMID>
  </reference>
  <reference>
    <citation>Azoulay D, Lucidi V, Andreani P, Maggi U, Sebagh M, Ichai P, Lemoine A, Adam R, Castaing D. Ischemic preconditioning for major liver resection under vascular exclusion of the liver preserving the caval flow: a randomized prospective study. J Am Coll Surg. 2006 Feb;202(2):203-11.</citation>
    <PMID>16427543</PMID>
  </reference>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 11, 2014</study_first_submitted>
  <study_first_submitted_qc>June 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2014</study_first_posted>
  <last_update_submitted>June 18, 2014</last_update_submitted>
  <last_update_submitted_qc>June 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 20, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Eastern Hepatobiliary Surgery Hospital</investigator_affiliation>
    <investigator_full_name>Wei-feng Yu</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>hepatic ischemia reperfusion injury</keyword>
  <keyword>ischemia precondition</keyword>
  <keyword>remote ischemia precondition</keyword>
  <keyword>anti-inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

